drugset / Trial / NCT05308602
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years
RandomizedParallel-groupTriple-blindPrevention
Summary
The objective of the study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E, comparing the immunogenicity data against Beta (B.1.351), Delta (B.1.617.2), Omicron (B.1.1.529) and other variants with Sinopharm inactivated COVID-19 vaccine or mRNA vaccine.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2022-08-01
- Completion
- 2023-08-01
Outcome
Outcome not reported
Stopped: “There was not a need any more.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCTV01C | Vaccine | — | Intramuscular |
| Subject | SCTV01E | Vaccine | — | Intramuscular |
| Comparator | Sinopharm inactivated COVID-19 vaccine | Vaccine | — | Intramuscular |
| Comparator | mRNA vaccine manufactured by Pfizer or Moderna | Messenger RNA (mRNA) | — | Intramuscular |